Comparative Effectiveness of POC-A1c vs the Current Standard Based on OGTT for Early Detection DM2 in Colombia

Diabetes Mellitus, Type 2 Clinical Trial

— EDDIT-1  

Official title:

Comparative Effectiveness of Point-of-care Glycosylated Hemoglobin Measurement (POC-A1c) vs the Current Standard Based on Oral Glucose Tolerance Test for Early Detection of Type 2 Diabetes Mellitus (DM2) in Colombia

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05440968
• Other study ID #: CGIS-DM-001-18
• Status: Active, not recruiting
• Phase: N/A
• Start date: June 30, 2022
• Est. completion date: September 20, 2023

Study information

• Verified date: August 2023
• Source: Centro de Atencion e Investigacion Medica
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the impact of conducting a screening questionnaire (FINDRISC) and the implementation of a point-of-care HBA1c test for those with identified risk to suffer Diabetes in ten years, to improve the proportion of patients attending for a confirmatory test ( oral glucose tolerance test ) and evaluate the impact of such a strategy to minimize type 2 diabetes outcomes.

Description:

The physician explains the study´s consistency and obtains informed consent. If the patient accepts, the FINDRISC will be checked, the inclusion and exclusion criteria will be verified and the pertinent data from the patient's medical history will be recorded in a computer.

Subsequently, subjects will be included in the study and randomized into two groups. In group A (intervention) participants will be offered information on healthy lifestyles according to their score on the FINDRISC questionnaire and subsequently a POC-A1c measurement. Participants in group B (control) will be offered the same information on healthy lifestyles according to their FINDRISC score.

Additionally, all randomized participants will be invited to undergo an oral glucose tolerance test in the CAIMED allied laboratory or in the laboratory of their choice or through their health care provider with the necessary preparation recommendations for the performance of the test. For this purpose, they will be given an order that includes the date of the screening, a follow-up number and a window of time in which they should go (i.e., 30 days and with a second attempt - maximum window at 90 days).

After 30 days from the application of the screening from the delivery of the order for the OGTT, a call will be made to the randomized subjects to check the result of the OGTT if the test was taken and request its result in case it was taken, if the test was taken, it should refer the same to the center. Otherwise, the causes of loss to follow-up will be inquired not having previously performed the recommended OGTTand a new call will be made at 90 days. In patients who, if they attended the OGTT and obtained a presumptive result of diabetes (defined as an altered oral glucose tolerance test and/or altered POC - A1C test according to American Diabetes Association guidelines), a close call will be made 30 days after the test was performed to confirm whether they initiated control of their disease. For this, it will be indicated to them that they must attend a consultation by general medicine according to what is contemplated by their benefit plan administration entity, social security administrator, giving completion to the follow-up.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 902
• Est. completion date: September 20, 2023
• Est. primary completion date: November 2, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Adult, aged greater than or equal to 18 years and less than or equal to 75 years.

• Understands, accepts and agrees to sign the informed consent form.

• FINDRISC greater than or equal to 12

Exclusion Criteria:

Previous diagnosis of type 1 or type 2 diabetes mellitus.

• Pregnancy or breastfeeding at the time of inclusion in the study (referred by the subject).

• History of cancer in the subject (must be in remission for 5 years).

• Known history of familiar hyperlipidemia.

• Chronic use of systemic corticosteroids (Defined as: a dose greater than 5 mg of oral prednisolone or its equivalent and/or consumption greater than one month of the same).

• Known history of hemophilia or other coagulation disorders.

• Known history of stage IV or V chronic kidney disease.

• Known history of HIV (on antiretroviral therapy).

• History of sickle cell disease

• Known history of glucose-6-phosphate dehydrogenase deficiency

• Known history of blood transfusion in the last 3 months

• Known history of erythropoietin therapy in the last 6 months

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Other:
• Point of Care - Glycated Hemoglobin (A1c)
Test for diagnosis of Diabetes through a Point of care device
• Oral Glucose Tolerance Test
Routinary diagnosis diabetes test by venous blood sample

Locations

Country	Name	City	State
Colombia	Maria Granados	Bogotá

Sponsors (1)

Lead Sponsor	Collaborator
Humberto Reynales MD MSc PhD

Country where clinical trial is conducted

Colombia, 

References & Publications (9)

8. Mariano Cantillo HJ, Ocampo DF, Cuello Santana KL. Uso del instrumento FINDRISK para identificar el riesgo de prediabetes y diabetes mellitus tipo 2. Revista Repertorio de Medicina y Cirugía. 2019 Oct 25;28(3):157-63.

American Diabetes Association. Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers. Clin Diabetes. 2022 Jan;40(1):10-38. doi: 10.2337/cd22-as01. No abstract available. — View Citation

Barengo NC, Tamayo DC, Tono T, Tuomilehto J. A Colombian diabetes risk score for detecting undiagnosed diabetes and impaired glucose regulation. Prim Care Diabetes. 2017 Feb;11(1):86-93. doi: 10.1016/j.pcd.2016.09.004. Epub 2016 Oct 7. — View Citation

Barengo NC, Tuomilehto JO. How can we identify candidates at highest risk--to screen or not to screen? Herz. 2016 May;41(3):175-83. doi: 10.1007/s00059-016-4417-5. — View Citation

Barry E, Roberts S, Oke J, Vijayaraghavan S, Normansell R, Greenhalgh T. Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. BMJ. 2017 Jan 4;356:i6538. doi: 10.1136/bmj.i6538. — View Citation

Jani IV, Peter TF. How point-of-care testing could drive innovation in global health. N Engl J Med. 2013 Jun 13;368(24):2319-24. doi: 10.1056/NEJMsb1214197. No abstract available. — View Citation

Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020 Mar;10(1):107-111. doi: 10.2991/jegh.k.191028.001. — View Citation

Khunti K, Gavin JR 3rd, Boulton AJM, Blickstead R, McGill M, Ceriello A, Raz I, Sadikot S, Wood DA, Cos X, Kalra S, Das AK, Espinosa Lopez C; Berlin Declaration Steering Group. The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important? Prim Care Diabetes. 2018 Oct;12(5):383-392. doi: 10.1016/j.pcd.2018.04.003. Epub 2018 May 8. — View Citation

Vandersmissen GJ, Godderis L. Evaluation of the Finnish Diabetes Risk Score (FINDRISC) for diabetes screening in occupational health care. Int J Occup Med Environ Health. 2015;28(3):587-91. doi: 10.13075/ijomeh.1896.00407. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Attendance of patients with knowledge of their risk for diabetes type 2 to a confirmatory test, oral glucose tolerance test	Through follow up calls and report of oral glucose tolerance test, compare the attendance arm who had Point of care of A1C with the one who didn´t	up to 90 days
Secondary	Number of days that determine the application of POC-A1c compared to the current recommendations from the American Academy of Diabetes (OGTT).	Through follow up calls and report of oral glucose tolerance test, compare the attendance arm who had Point of care of Hb1Ac with the one who didn´t	30 to 90 days
Secondary	number of patients attending the confirmatory testing as adherence to their primary care physician's recommendations and clinical practice guidelines	Through follow up calls and report of oral glucose tolerance test, in a window stablished by 30 and 90 days. Compare the attendace arm who had Point of care of Hb1Ac with the one who didn´t	30 and 90 days
Secondary	Describe the causes of non-performance of the confirmatory test throughout a brief questionnaire	Identification of predictors of non-performance or postponement of the diagnostic test within a maximum of 90 days from the initial recommendation.	up to 90 days